leadf
logo-loader
viewWillow Biosciences Inc.

Willow Biosciences closes C$11.5M offering for cannabinoid commercialization

The company offered roughly 17.7 million units, each containing one share and one half a purchase warrant, at a price of C$0.65 per unit

Cannabis leaf on $100 bills
Willow has developed a proprietary process to produce high purity, plant-derived CBG and CBD compounds for the global pharmaceutical, health and wellness and consumer packaged goods industries

Willow Biosciences Inc (TSE:WLLW) (OTCQX:CANSF) has closed its previously announced upsized public offering of C$11.5 million, which the company plans to use for the commercialization of cannabigerol (CBG) and other portfolio cannabinoids.

The company offered roughly 17.7 million units, each containing one share and one half a purchase warrant, at a price of C$0.65 per unit. This includes 2.3 million units issued due to the exercising of an over-allotment option. 

Each warrant entitles its holder to acquire a common share at a price of C$0.85 for two years. Should the company's stock trade above C$1.20 on the Toronto Stock Exchange for 10 consecutive trading days, Willow can move up the expiry date, with notice.

READ: Willow Biosciences boosts offering to $10 million due to excess demand

The warrants will be listed and posted for trading on the TSX under the symbol WLLW.WR on Thursday.

Willow paid a syndicate of agents including ATB Capital Markets Inc, Canaccord Genuity Corp and Eight Capital a cash commission equal to 3% of the gross proceeds of the offering received from investors included by the company on a president's list and 6.0% of the remaining gross proceeds. The company also issued the Agents 474,324 common share purchase warrants, which are exercisable at C$0.85 for a period of one year.

Vancouver-based Willow has developed a proprietary process to produce high purity, plant-derived CBG and CBD compounds for the global pharmaceutical, health and wellness, and consumer packaged goods industries.

In addition to commercialization, proceeds will go towards general administrative expenses, working capital and other corporate purposes.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Willow Biosciences Inc.

Price: 0.63 CAD

TSX:WLLW
Market: TSX
Market Cap: $60.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Willow Biosciences Inc. named herein, including the promotion by the Company of Willow Biosciences Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Willow Biosciences announces game changing successful production of pure CBG...

Willow Biosciences (TSE: WLLW-OTCQX: CANSF) President and CEO Trevor Peters joined Steve Darling from Proactive with news the company has successfully developed a scalable process for producing cannabigerol with greater than 99% purity and no detectable THC at 500-litre scale. Peters...

on 09/21/2020

2 min read